Iovance Biotherapeutics
Iovance Biotherapeutics Inc is an American biotechnology company pioneering novel cancer cell therapies using tumor-infiltrating lymphocytes. The company develops and commercializes autologous cell therapies designed to harness the human immune system to target solid tumors. Revenue is generated from commercial sales of its approved cell therapy products alongside clinical development partnerships. Core end markets encompass specialized oncology centers, academic research hospitals, and cancer treatment facilities in the United States and global markets. Iovance holds a pioneering position in the biopharmaceutical sector as a developer of approved TIL cell therapies for solid tumor oncology. The company is headquartered in San Carlos, California, and its common stock is traded on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Iovance Biotherapeutics.
- Legal name
- Iovance Biotherapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Iovance Biotherapeutics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.23 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)